Please login to the form below

Not currently logged in
Email:
Password:

abiraterone

This page shows the latest abiraterone news and features for those working in and with pharma, biotech and healthcare.

EMA starts review of Xtandi in non-metastatic prostate cancer

EMA starts review of Xtandi in non-metastatic prostate cancer

At the moment Xtandi - like longstanding rival Zytiga (abiraterone acetate) from Johnson &Johnson - is only prescribed for men with advanced CRPC that has spread and no longer responds to hormone therapy.

Latest news

More from news
Approximately 5 fully matching, plus 63 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    outperforming J&J's Zytiga [abiraterone].

  • Taking a strategic approach Taking a strategic approach

    But in oncology Zytiga (abiraterone) was last year not recommended for an early use indication in final draft guidance from NICE, but that appraisal process is currently on hold after Janssen

  • Pharma deals during October 2013 Pharma deals during October 2013

    AstraZeneca is focusing on developing its regional oncology portfolio as evidenced by the closure of a co-promotion deal with Janssen in Japan for Zytiga (abiraterone acetate), an innovative oral therapy

  • Interview: Cesar Rodriguez, Janssen Interview: Cesar Rodriguez, Janssen

    Janssen is developing its strengths in other areas too, and Rodriguez noted the company's recent developments in oncology, including the launch of abiraterone acetate for prostate cancer – it's “ a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics